Clinical Policy: Alopecia Areata Treatments
Customize your policy alerts
Sign up for mhn Policy HNCA.CP.CPA.04 alerts
Get alerted when Policy HNCA.CP.CPA.04 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) for treating alopecia areata for applicable commercial and HIM lines of business.
Health Insurance Marketplace (HIM) use of these products for alopecia areata is a benefit exclusion and will not be authorized because it is considered cosmetic in nature.
Coverage Criteria
Initial Therapy — Covered when ALL of the following are met.
Covered when ALL of the following are met:
Provider must submit supporting documentation (office chart notes, lab results, or other clinical information).
Continuation Therapy — Continued therapy covered when ALL of the following are met.
Continued therapy is covered when ALL of the following are met:
Approval duration: 12 months.
Requests for treatment of alopecia areata with the JAK inhibitors listed in this policy will be evaluated under the policy criteria; however, Health Insurance Marketplace (HIM) members are excluded from coverage for these indications because use for alopecia areata is considered cosmetic and will not be authorized. Provider documentation supporting medical necessity must still be submitted for non‑HIM members (see Provider Actions).
Combination therapy with other systemic immunosuppressive agents is not permitted. Specifically, concomitant use with biological DMARDs, other JAK inhibitors, or other potent immunosuppressants is prohibited due to additive immunosuppression and associated increased risks. Requests that propose combination use will be denied.
Prior authorization is required for baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) and approvals are contingent upon meeting the policy's clinical criteria (severity threshold, prior therapy requirements, prescriber specialty/consultation, age restrictions, and product‑specific dose limits).
This policy does not authorize use of the listed JAK inhibitors for non‑FDA approved indications unless such use is specifically addressed by the applicable off‑label or formulary policies. For commercial lines of business, refer to off‑label policy CP.CPA.09; requests lacking sufficient documentation of efficacy and safety per those policies will not be approved.
Exercise caution and do not approve requests that combine a JAK inhibitor with other potent immunosuppressive therapies. Combination use with biologic DMARDs, other JAK inhibitors, or potent immunosuppressants is not authorized because of additive immunosuppression, an increased risk of malignancy, and an increased risk of serious infections. Such combination therapy will be denied.
Coding and Severity Thresholds
Provider Actions and Requirements
Prior authorization required for Olumiant, Litfulo, and Leqselvi
Prior authorization is required for Baricitinib (Olumiant), Ritlecitinib (Litfulo), and Deuruxolitinib (Leqselvi) for the treatment of alopecia areata. Approval is contingent on meeting the policy criteria including diagnosis of severe AA (>50% scalp hair loss), episode >6 months, dermatology prescribing/consultation, product-specific age limits, trial of at least one listed prior therapy, prohibition on combination immunosuppressive therapy, and adherence to product-specific dose limits.
- Affected products: Baricitinib (Olumiant), Ritlecitinib (Litfulo), Deuruxolitinib (Leqselvi).
- Approval requires meeting all policy criteria (severity, duration, prescriber specialty, age, prior therapy, combination use restrictions, and dose limits).
Prior therapy required (one of listed options)
Member must have tried at least one of the following prior therapies before approval: a conventional systemic therapy, a high- or super-high potency topical corticosteroid, or topical immunotherapy (e.g., DPCP or SADBE).
- Conventional systemic therapy (examples: corticosteroids, methotrexate, cyclosporine).
- High- or super-high potency topical corticosteroid.
- Topical immunotherapy (e.g., diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE)).
- Exception: requirement for a trial of a conventional systemic agent may be waived if the patient has already tried Olumiant, Litfulo, or Leqselvi.
Submit clinical documentation to support approval
Provider must submit supporting documentation such as office chart notes, laboratory results, or other clinical information demonstrating that the member meets all approval criteria.
- Documentation should verify diagnosis of severe AA (>50% scalp hair loss), duration of current episode (>6 months), dermatology involvement, prior therapy trials, and current dosing.
- Include labs or other clinical data as needed to support safety and appropriateness.
Exclusions that will trigger denial
Certain requests will be denied: use of these products for Health Insurance Marketplace (HIM) members for alopecia areata is excluded as cosmetic; combination use with biologic DMARDs, other JAK inhibitors (including topical JAK inhibitors), or potent immunosuppressants is not authorized.
- HIM benefit exclusion: use of Olumiant, Litfulo, or Leqselvi for AA in Health Insurance Marketplace members will not be authorized as it is considered cosmetic.
- Combination therapy with biologic DMARDs, other JAK inhibitors, or potent immunosuppressants (e.g., azathioprine, cyclosporine) is prohibited and requests for such use will be denied.
Background
Alopecia areata severity is classified by the percent of scalp hair loss; severe alopecia areata is defined as ≥ 50% scalp hair loss (extent of scalp hair loss between approximately 50% and 100%).
Janus kinase (JAK) inhibitors including baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi) are FDA‑approved for severe alopecia areata in specified age groups and have product‑specific dosing and age restrictions. Use is subject to prior authorization and the policy’s criteria, including requirements for prior therapy, dermatology involvement, and prohibition of combination immunosuppressive regimens.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.